Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 1218 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2019  |  Volume : 23  |  Issue : 3  |  Page : 307-311

Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study

1 Department of Diabetes and Metabolic Disorders, Care and Cure, New Delhi, India
2 Department of Diabetes and Metabolic Disorders, The Specialist Clinic, New Delhi, India
3 Department of Diabetes and Metabolic Disorders, Kanishka Health Care, New Delhi, India
4 Department of Orthopaedics, Care and Cure, New Delhi, India
5 BA, LLB (HONS), New Delhi, India

Correspondence Address:
Pankaj Aneja
Sector 8, A1, House No 81, Rohini, Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijem.IJEM_55_19

Rights and Permissions

Background and Aims: To assess the efficacy and safety of canagliflozin (CANA, 300 mg/d) in overweight and obese patients with type 2 diabetes mellitus (T2DM). Methods: In a single centre, retrospective, observational study, we included overweight or obese patients with T2DM who had HbA1c >7% and received CANA as addition to existing therapy for at least 24 weeks. Primary endpoint assessed was changes in HbA1c, fasting and post-prandial plasma glucose (FPG and PPG), and secondary endpoints included changes in weight, waist circumference (WC), systolic blood pressure (SBP) and diastolic BP (DBP) over 12 and 24 weeks. Results: Among 90 patients, mean age was 53.5 ± 10.8 years and 42.2% were females. Majority of the patients (46.7%) were receiving two antidiabetic drugs. Significant reduction in HbA1c from baseline to week 24 (9.1 ± 1.8% vs. 7.5 ± 1.1% respectively, mean difference: -1.6 ± 0.9%, P < 0.0001) was seen. Reduction in FPG (mean difference: -63.0 ± 45.2 mg/dL, P < 0.0001) and PPG (mean difference: -97.7 ± 54.3 mg/dL, P < 0.0001) was also significant. Mean reduction in weight was -4.3 ± 2.2 kg (P < 0.0001) at 24 weeks. Reductions in WC, SBP and DBP were also significant at week 24 (P < 0.0001 for all). Changes in all these parameters were also significant at week 12. Proportion of patients achieving the target HbA1c of <7% was 28.9% and 52.2% at week 12 and week 24, respectively. Genital mycotic infections were seen in 20% patients and was present in higher proportion of females than males (28.9% vs. 13.5%, P = 0.070). No episodes of hypoglycaemia were found. Conclusion: Canagliflozin should be considered from among the various antidiabetic drugs in overweight and obese patients with T2D in India.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded198    
    Comments [Add]    
    Cited by others 1    

Recommend this journal